Updates:

Lilly Canada’s Coronavirus Response

All of Lilly Canada’s medicines are in stock and available. If you are having difficulty securing a quantity of a Lilly medicine for yourself or a pharmacy, please contact us at
1-888-545-5972.

How we’re managing our supply of medicines:

Among the concerns raised by the novel coronavirus is the question of whether patients can count on a reliable supply of medicine. Since the initial outbreak, Lilly has closely monitored our supply chain for potential impact to the supply of our medicines around the world. We continue to monitor the situation, and our insulin manufacturing sites in the U.S. and Europe remain operational, with increased precautions in place to protect the supply of medicine and the welfare of our employees. If the situation changes, our intention is to post an update promptly on this site and on www.drugshortagescanada.ca. That said, again, we do not currently anticipate shortages for any of our medicines.

How we’re helping to ensure fair access to our medicines:

Lilly is encouraging responsible re-stocking practices to help ensure fair access to our medicines, by asking pharmacies to: 

  • responsibly re-stock, and dispense to patients based on their typical needs.
  • consider implementing the supply recommendations made by The Canadian Pharmacists’ Association: “To ensure that Canada’s medication supply is managed responsibly, we are recommending a 30-day supply of medications for patients, unless clinically justified.” These recommendations have been adopted or mandated by several provinces.
  • proactively reach out to us if they cannot access Lilly medicines or devices.

Some wholesalers have implemented order limits to ensure equitable access for all Canadians. These order limits do not imply a product shortage.If a patient requires a Lilly medication and their pharmacy doesn't have it, the pharmacy has guidance from Lilly on how to escalate the request. Again, we do not currently anticipate shortages for any of our medicines.

How we’re working differently:

Also, out of an abundance of caution and to help reduce the spread of infection, we at Lilly have made the decision to shift all of our face-to-face meetings to virtual meetings. This includes meetings between employees, meetings with healthcare professionals, and meetings with other stakeholders in the healthcare system. We’re taking these steps to protect the health and safety of patients, our employees, and the healthcare community. 

Further, Lilly recently announced an agreement with a Canadian company—AbCellera—to co-develop antibodies for the potential treatment and prevention of COVID-19, which is the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. You can read more about this collaboration in this story by the CBC.

If you have any questions, please contact us at 1-888-545-5972.